AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

NASDAQ:UMRXUnum Therapeutics Stock Price, Forecast & News

$0.55
-0.01 (-1.97 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.51
Now: $0.55
$0.56
50-Day Range
$0.37
MA: $0.46
$0.59
52-Week Range
$0.30
Now: $0.55
$3.65
Volume344,800 shs
Average Volume423,475 shs
Market Capitalization$17.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33
Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Unum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UMRX
CUSIPN/A
Phone617-945-5576

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.50 million
Book Value$1.04 per share

Profitability

Net Income$-31,830,000.00

Miscellaneous

Employees72
Market Cap$17.07 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.

Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions

How has Unum Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Unum Therapeutics' stock was trading at $0.3736 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UMRX shares have increased by 46.7% and is now trading at $0.5479. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Unum Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Unum Therapeutics.

When is Unum Therapeutics' next earnings date?

Unum Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Unum Therapeutics.

How were Unum Therapeutics' earnings last quarter?

Unum Therapeutics Inc (NASDAQ:UMRX) released its quarterly earnings data on Monday, May, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. The company earned $7.03 million during the quarter, compared to analyst estimates of $3 million. Unum Therapeutics had a negative return on equity of 83.39% and a negative net margin of 99.09%. View Unum Therapeutics' earnings history.

What price target have analysts set for UMRX?

5 brokers have issued 1-year price objectives for Unum Therapeutics' shares. Their forecasts range from $1.00 to $6.00. On average, they expect Unum Therapeutics' stock price to reach $3.50 in the next year. This suggests a possible upside of 538.8% from the stock's current price. View analysts' price targets for Unum Therapeutics.

What are Wall Street analysts saying about Unum Therapeutics stock?

Here are some recent quotes from research analysts about Unum Therapeutics stock:
  • 1. According to Zacks Investment Research, "Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. " (5/30/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $18/share is based on an equally-weighted composite of: (a) $18.0/share, as a 25x multiple of taxed and diluted $7.63 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.5/share (discounted cash flow analysis using a 18.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2019)

Has Unum Therapeutics been receiving favorable news coverage?

Media headlines about UMRX stock have trended very negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Unum Therapeutics earned a daily sentiment score of -3.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutUnum Therapeutics.

Are investors shorting Unum Therapeutics?

Unum Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 362,200 shares, an increase of 14.2% from the April 30th total of 317,300 shares. Based on an average daily trading volume, of 435,800 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.5% of the company's shares are sold short. View Unum Therapeutics' Current Options Chain.

Who are some of Unum Therapeutics' key competitors?

What other stocks do shareholders of Unum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unum Therapeutics investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK), ADMA Biologics (ADMA), AzurRx BioPharma (AZRX), Miragen Therapeutics (MGEN), Polarityte (PTE), KushCo (KSHB) and Titan Pharmaceuticals (TTNP).

Who are Unum Therapeutics' key executives?

Unum Therapeutics' management team includes the following people:
  • Dr. Charles Wilson, CEO, Pres & Director (Age 55, Pay $807.42k)
  • Mr. Matthew S. Osborne, Chief Financial Officer (Age 48, Pay $517.98k)
  • Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
  • Mr. John L. Green C.A., C.P.A., Principal Accounting Officer (Age 40)
  • Mr. Larry Weiner, VP of Technical Operations

When did Unum Therapeutics IPO?

(UMRX) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

What is Unum Therapeutics' stock symbol?

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

How do I buy shares of Unum Therapeutics?

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unum Therapeutics' stock price today?

One share of UMRX stock can currently be purchased for approximately $0.55.

How big of a company is Unum Therapeutics?

Unum Therapeutics has a market capitalization of $17.07 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Unum Therapeutics employs 72 workers across the globe.

What is Unum Therapeutics' official website?

The official website for Unum Therapeutics is www.unumrx.com.

How can I contact Unum Therapeutics?

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.